Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks
Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF’s and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89% over Fridays’ close and 519% YTD! Pharmasset has no revenues but has a three...
Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars
Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year revenues at $228M .Also the Center for Medicare and Medicaid Services updated their...
Fidelity Biotech Fund (FBIOX) up 7.9% YTD Outperforms Major ETFs
Managed Healthcare Mutual Funds Starting To OutPerform ETFs Earlier this year we wrote an article on Investor Uprising comparing returns on biotech funds and major ETFs. At the time ETF’s were outperforming managed mutual funds. Now as we enter the strong quarter for small cap and biotech...
Macro Rules: Gold Gains Strength As Fiat Currency Update – 1
Volatile schizoid markets- Not a Good Time to Add Positions in the Life Sciences It is very hard to focus on biotech stocks with all the financial distress and chaos in the Eurozone dominating the news. Last week it was Greece today it is Italy and the PIIGS. As debt concerns mount the new...
MFGlobal: Where is the Customer Money?
Many of you read about the bankruptcy of MFGlobal last week. What you may not know is that customers still cannot access their cash.If they have open positions they have been transferred to R.J.O’Brien. See story below. We have talked to several individuals with major brokerage houses and have...
